Antibody therapeutics: A new era for EGFR-mutant NSCLC treatment.
A major focus of this review is antibody-drug conjugates (ADCs) targeting novel surface antigens, including HER2, HER3, and TROP2, which have demonstrated remarkable clinical efficacy in EGFR TKI-resistant settings.